Objective: ODIN (Once-daily Darunavir In treatment-experieNced patients) was a phase III, 48-week, open-label study comparing once-daily vs. twice-daily darunavir/ ritonavir (DRV/r) in treatment-experienced patients with no DRV resistance-associated mutations (RAMs) at screening.
Introduction
Current therapeutic options for the treatment of HIV provide high rates of sustained virologic suppression and good tolerability, thereby reducing morbidity and mortality [1] . However, simplified dosing regimens, including once-daily dosing, are still needed for the improvement of patient convenience and adherence to long-term treatment [2] [3] [4] .
As part of combination therapy, the protease inhibitor darunavir (DRV) administered with low-dose ritonavir (DRV/r) is approved in the USA, Europe, and other countries for the treatment of antiretroviral-naive, HIV-1-infected adults at a dose of 800/100 mg oncedaily and for treatment-experienced patients at a dose of 600/100 mg twice-daily [1, 5] . Once-daily DRV/r 800/ 100 mg demonstrated durable efficacy and tolerability in treatment-naive patients in the ARTEMIS (Anti-Retroviral Therapy with TMC114 ExaMined In naive Subjects) trial, establishing noninferiority (HIV-1 RNA < 50 copies/ml) to lopinavir/ritonavir (once-daily or twice-daily) over 96 weeks [6] . The efficacy and safety of twice-daily DRV/r 600/100 mg was established in treatment-experienced, lopinavir-naive patients in the TITAN (TMC114/r In Treatment-experienced pAtients Naïve to lopinavir) trial [7] .
This study set out to investigate the potential benefits of a once-daily DRV/r dosing regimen in a treatmentexperienced patient population. Once-daily DRV/r 800/100 mg has been previously investigated in an exploratory analysis in highly treatment-experienced patients over 24 weeks [8, 9] . In the early dose-finding stages of the POWER (Performance Of TMC114/r When Evaluated in treatment-experienced patients with PI Resistance) 1 and 2 trials, a subgroup of patients with no baseline DRV resistance-associated mutations (RAMs) achieved virologic suppression rates [HIV-1 RNA < 50 copies/ml; intent-to-treat/time-to-loss of virologic response (ITT-TLOVR)] of 66.7% (14/21) and 62.1% (18/29) with once-daily DRV/r 800/100 mg and twice-daily DRV/r 600/100 mg, respectively [10] .
In the present study, the 48-week efficacy, safety, and tolerability of once-daily DRV/r 800/100 mg vs. twicedaily DRV/r 600/100 mg was assessed in a larger number of treatment-experienced, HIV-1-infected adult patients who had no DRV RAMs at screening.
Methods

Patient population
Patients recruited to ODIN (TMC114-C229; Oncedaily Darunavir In treatment-experieNced patients) were treatment-experienced, HIV-1-infected adults (!18 years), with a plasma HIV-1 RNA more than 1000 copies/ml, CD4 cell count more than 50 cells/ml, and none of the 11 DRV RAMs (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V) [11, 12] detected at screening. The absence of DRV RAMs was considered an appropriate marker for early treatment experience. Patients needed to be receiving a stable HAART regimen for at least 12 weeks at screening. Patients with past or current treatment with enfuvirtide, tipranavir, and/or DRV were excluded. Patients with chronic hepatitis B and/or C were allowed to enroll if their condition was clinically stable and they were not expected to require treatment during the study period. Other exclusion criteria included the presence of any active AIDS-defining illness (with the exception of stable cutaneous Kaposi's sarcoma and wasting syndrome) or active clinically significant disease (for example tuberculosis), use of disallowed concomitant therapy, pregnancy/ breastfeeding, clinical/laboratory evidence of significantly decreased hepatic function, decompensation or acute viral hepatitis, or presence of any grade 3/4 laboratory abnormality (except asymptomatic triglyceride or cholesterol elevations, or bilirubin increases in patients on atazanavir at screening).
Study design
ODIN was a randomized, open-label, phase III trial comparing the efficacy, safety, and tolerability of oncedaily DRV/r 800/100 mg vs. twice-daily DRV/r 600/ 100 mg, and an optimized background regimen (OBR), over 48 weeks in treatment-experienced patients with no DRV RAMs at screening. The trial consisted of a screening period (up to 4 weeks), a 48-week treatment period, and a 4-week follow-up.
Patients were stratified by screening HIV-1 RNA ( 50 000 copies/ml or > 50 000 copies/ml; this cutoff was established as HIV-1 RNA 50 000 copies/ml was the approximate median baseline HIV-1 RNA for patients failing current therapy in previous DRV/r studies) [7] [8] [9] . Patients were randomized in a 1 : 1 ratio to receive oncedaily DRV/r 800/100 mg or twice-daily DRV/r 600/ 100 mg and an individualized OBR, chosen by the investigator prior to randomization, and consisting of at least two nucleoside reverse transcriptase inhibitors (NRTIs) based on antiretroviral history and resistance testing. Use of other protease inhibitors, nonnucleoside reverse transcriptase inhibitors (NNRTIs), enfuvirtide, raltegravir, maraviroc, or investigational agents in the OBR was not allowed. A centralized randomization system was used; at the baseline visit, the investigator called the interactive voice/web response system and patients were randomly assigned according to a predefined randomization list, constructed via random permuted blocks to ensure balance across treatments groups in each baseline HIV-1 RNA stratum.
The primary objective was to establish noninferiority of once-daily DRV/r 800/100 mg to twice-daily DRV/r 600/100 mg in confirmed virologic response (HIV-1 RNA < 50 copies/ml) using an ITT-TLOVR algorithm at week 48, with a predefined noninferiority margin (delta) of 12%. The primary analysis was performed when all actively enrolled patients had either completed 48 weeks of treatment or discontinued.
Written informed consent was obtained from all study participants. The study protocol was reviewed and approved by the appropriate review boards or institutional ethics committees and health authorities, and was conducted in accordance with the Declaration of Helsinki.
Study evaluations and statistical methods
Plasma HIV-1 RNA measurements and safety assessments were performed at screening, baseline, and each visit (weeks 4, 8, 12, 24, 36, and 48 or withdrawal). For efficacy assessments, the TLOVR algorithm was used to determine virologic response, defined as HIV-1 RNA less than 50 copies/ml. The ITT population included all randomized patients who took at least one dose of trial medication, irrespective of protocol compliance; the perprotocol population included all randomized patients who were compliant with respect to the intake of trial medication (therefore, did not take any disallowed medication for ! 1 week). The ITT population was used to evaluate noninferiority; efficacy assessments were also performed using the per-protocol population. Two-sided 95% confidence intervals (CIs) were derived to compare treatment groups at all timepoints; if at week 48, the lower limit of the 95% CI of the difference between groups was higher than -12%, noninferiority of once-daily DRV/r to twice-daily DRV/r could be concluded. Consistent with earlier studies [6, 7] , a predefined delta of -12% was considered appropriate as it was small relative to observed differences between twice-daily DRV/r 600/100 mg and control protease inhibitor(s) in previous studies. Plasma viral loads were determined using the Roche Amplicor HIV-1 monitor test (version 1.5). Virologic response was also analyzed by screening stratification factor (HIV-1 RNA 50 000 or > 50 000 copies/ml). Change over time in CD4 cell count from baseline to week 48 was calculated using the last observation carried forward (LOCF) analysis.
Resistance determinations were performed routinely on samples with HIV-1 RNA at least 1000 copies/ml taken at screening, baseline, week 24, and week 48 (or withdrawal). Additional testing was performed on samples from virologic failures with HIV-1 RNA at least 50 copies/ml. Phenotypic and genotypic determinations were performed by Virco BVBA (Mechelen, Belgium) by Antivirogram and VircoTYPE HIV-1, respectively. HIV-1 isolates were considered susceptible to a drug if the fold-change was below or equal to the low clinical or biologic cut-off. The TLOVR nonvirologic failure-censored algorithm was used to identify virologic failures, in which changes at timepoints after discontinuation were not imputed for patients who discontinued for reasons other than virologic failure, except for patients whose viral load increased to at least 50 copies/ml immediately before discontinuation. Patients with virologic failure were defined as those treated for at least 12 weeks and either never suppressed (never achieved two consecutive HIV-1 RNA values < 50 copies/ml) or rebounders (two consecutive HIV-1 RNA values < 50 copies/ml, followed by either two consecutive values !50 copies/ml, or discontinued with a last observed viral load !50 copies/ml).
Patient adherence was assessed by three methods: the Modified-Medication Adherence Self-Report Inventory (M-MASRI) questionnaire: mean week 4-48 adherence was converted to a binary variable to determine adherence (>95%) or suboptimal adherence ( 95%); DRV plasma concentration: above (adherent) or below (suboptimally adherent) the detection limit of 10 ng/ml; and pill count, calculated as (actual amount/amount to be taken) Â 100, converted to a binary variable to determine adherence (>95%) or suboptimal adherence ( 95%). Blood samples were taken at weeks 4, 8, 24, and 48 to determine DRV trough concentrations for the aforementioned adherence assessments as well as for pharmacokinetic evaluations.
The ITT population was used for the safety analysis. Safety was assessed by adverse event data, clinical laboratory tests (hematology, coagulation tests, biochemistry, urinalysis, and hepatitis serology/viremia), cardiovascular variables (vital signs and electrocardiogram), and physical examination. An independent Data and Safety Monitoring Board was implemented for continued review of the safety data. Adverse events and laboratory abnormalities were graded according to the Division of AIDS (DAIDS) Grading Table [13] and causality assessed by the study investigators.
Results
Patient demographics and baseline characteristics
Of 1092 patients screened, 590 patients from 21 sites in North, Central and South America, Europe, Australia, and Asia were randomized and treated with once-daily DRV/r 800/100 mg (n ¼ 294) or twice-daily DRV/r 600/100 mg (n ¼ 296) and an investigator-selected OBR ( Fig. 1 ).
Baseline characteristics were well balanced across treatment arms (Table 1) . Slightly more than one-third (36.1%) of patients were women; 35.9% were white, 26.3% black, 18.0% Hispanic, and 15.1% were Asian. Mean baseline HIV-1 RNA was 4.16 log 10 copies/ml and median CD4 cell count was 228 cells/ml. Overall, 46.1% of patients entering the trial were protease inhibitornaive, 28.3% had previously used at least two protease inhibitors, 57.2% had previously used at least three NRTIs, and 87.5% of patients had used at least one NNRTI ( Table 1 ). The majority of patients (84.2%) had no International AIDS Society-USA (IAS-USA) primary (major) protease inhibitor mutations [14] at baseline or prebaseline; the median number at (pre)baseline was 0 (range: 0-5). The median number of IAS-USA protease inhibitor RAMs [14] at (pre)baseline was three (range: 0-14); the median number of (pre)baseline NRTI RAMs was one (range: 0-8).
The NRTIs most frequently used in the OBR were tenofovir (81.2%), zidovudine (53.4%), and lamivudine (52.7%); 63% used a combination of two NRTIs and 34% used three [most frequently lamivudine, tenofovir, and zidovudine (24%)].
Overall, 89 patients (15.1%) prematurely discontinued the trial: 13.9% in the once-daily and 16.2% in the twicedaily arm (Fig. 1 ). Most discontinuations were due to adverse events (3.4% once-daily and 4.1% twice-daily) and lost to follow-up (3.1% once-daily and 4.4% twicedaily).
Efficacy
At week 48, 72.1% of once-daily and 70.9% of twicedaily DRV/r patients achieved HIV-1 RNA less than 50 copies/ml (ITT-TLOVR; Fig. 2a ). The difference in response was 1.2% (95% CI -6.1 to 8.5%; P < 0.001), establishing noninferiority of once-daily compared with twice-daily DRV/r. Noninferiority of once-daily DRV/r was also confirmed in the per-protocol population (73.4 vs. 72.5% once-daily vs. twice-daily patients achieved HIV-1 RNA < 50 copies/ml; difference in response: 0.9% (95% CI -6.7 to 8.4%; P < 0.001). In the TLOVR nonvirologic failure-censored analysis, 82.2% once-daily vs. 83.0% twice-daily patients achieved HIV-1 RNA less than 50 copies/ml [difference in response: -0.8% (95% CI -7.4 to 5.8%)].
Virologic responses by stratification factor (HIV-1 RNA 50 000 and > 50 000 copies/ml) were consistent across once-daily and twice-daily DRV/r treatment ( Fig. 2b ). Median CD4 cell count increases from baseline to week 48 were also similar across arms, at 100 and 94 cells/ml with once-daily and twice-daily DRV/r, respectively.
Adherence
Based on the M-MASRI data, a slightly higher percentage of patients taking once-daily DRV/r (63.1%) than twice-daily DRV/r (55.6%) had mean week 4-48 adherence more than 95% (P ¼ 0.0931, Fisher's exact test). For adherence measured by pill count, 57.5% of once-daily and 54.1% of twice-daily patients were considered adherent. A similarly large percentage of patients in each arm (83.2% once-daily and 87.6% twicedaily) had DRV concentrations above the detection limit of 10 ng/ml and were considered adherent.
Virology
Virologic failure rates (HIV-1 RNA > 50 copies/ml) were comparable for the once-daily and twice-daily DRV/r arms (P ¼ 0. the once-daily DRV/r arm, 54 (83.1%) were never suppressed and 11 (16.9%) were rebounders. In the twicedaily arm, 43 (79.6%) were never suppressed and 11 (20.4%) were rebounders.
The development of resistance in patients who failed virologically was rarely observed. Paired baseline/endpoint genotypes were available for 60 of the 65 virologic failures in the once-daily arm and 42 of the 54 virologic failures in the twice-daily arm. Of those with paired baseline/endpoint genotypes, protease inhibitor RAMs developed in seven (11.7%) once-daily patients and four (9.5%) twice-daily patients. One patient in the once-daily arm developed primary protease inhibitor mutations, which included the DRV RAMs V32I, L76V, and I84V. NRTI RAMs developed in four (6.7%) once-daily and three (7.1%) twice-daily virologic failure patients with paired baseline/endpoint genotypes.
Paired baseline/endpoint phenotypes were available for 59 and 41 virologic failures in the once-daily and twicedaily arms. No patients with paired baseline/endpoint phenotypes in the twice-daily DRV/r arm lost suscepti-bility to any protease inhibitor, but in the once-daily arm, two lost susceptibility to at least one protease inhibitor. One of these two patients lost susceptibility to DRV (as described above, this patient also developed DRV RAMs). Seven (11.9%) patients in the once-daily arm and four (9.8%) twice-daily patients lost susceptibility to an NRTI in the OBR.
Safety
Mean exposure was 44.8 weeks for the once-daily arm and 43.1 weeks for twice-daily DRV/r. Most adverse events were grade 1 or 2 in severity (75.5 and 75.7% of once-daily and twice-daily patients, respectively, reported ! 1 grade 1 or 2 adverse event, Table 2 ) [15] . Few patients in either arm had at least one adverse event leading to permanent discontinuation (3.4% in the oncedaily and 4.7% in the twice-daily arm). Serious adverse events (SAEs; 5.4 vs. 9.1%) and grade 3-4 adverse events (7.8 vs. 15.2%; P < 0.05) were reported in fewer patients with once-daily than twice-daily DRV/r (Table 2) ; however, no specific patterns were apparent in the incidence of individual SAEs or grade 3-4 adverse events.
SAEs at least possibly related to treatment occurred with a low incidence; rates and types of events were similar across treatment arms (Table 2) . However, the incidence of at least possibly treatment-related grade 3-4 adverse events was numerically lower for once-daily than twice-daily DRV/r (1.7 vs. 4.1%; Table 2 ).
Two patients in the once-daily arm and six in the twicedaily arm died during treatment, and a further patient in the once-daily arm died 4 days following treatment discontinuation; none was considered to be related to treatment. Deaths resulted from pneumonia and lymphoma, bacterial peritonitis; cardiorespiratory arrest and pneumonia; bronchopneumonia; uterine cancer; pneumonia, pulmonary bulla, and respiratory arrest; sepsis and bicytopenia; and uremic coma.
The most frequently reported adverse events considered at least possibly related to treatment (!2% incidence in either arm) were nausea, diarrhea, vomiting, rash, and headache ( Table 2) . A numerically higher incidence of diarrhea (15.2% twice-daily vs. 9.9% once-daily) was observed in the twice-daily arm; this was mainly driven by grade 1 events.
The overall incidence of laboratory abnormalities was low and generally comparable for the once-daily and twicedaily treatment arms, with most being grade 1 or 2 in severity ( Table 2 ). The most frequently reported treatment-emergent grade 2-4 lipid-related and liverrelated laboratory abnormalities (!2% incidence in either arm) were increased triglycerides, total cholesterol, lowdensity lipoprotein (LDL) cholesterol, aspartate aminotransferase (AST) and alanine aminotransferase (ALT; week 48 by stratification factor (screening HIV-1 RNA 50 000 or > 50 000 copies/ml). CI, confidence interval; DRV/r, darunavir/ritonavir. greatest for triglyceride elevations, which were half as frequent in the once-daily DRV/r arm (5.2 vs. 11.0% for twice-daily DRV/r; P < 0.05) but total and LDLcholesterol levels were also significantly lower in the once-daily arm ( Table 2) . Increases from baseline to week 48 in lipid-related laboratory parameters were generally very modest for both treatment arms, although smaller increases with once-daily than twice-daily DRV/r were observed for triglycerides and total cholesterol over the duration of the study (Fig. 3) . Lipid-lowering agents were received by 5.8 and 11.5% of patients in the once-daily and twice-daily arms, respectively. Grade 2-4 creatinine increases were reported in 11 (3.8%) once-daily patients and one (0.4%) twice-daily patient.
Pharmacokinetics
Pharmacokinetic data were available for 280 once-daily and 278 twice-daily patients. Median (range) DRV trough concentrations were 1896 ng/ml (184-7881 ng/ ml) for once-daily and 3197 ng/ml (250-11 865 ng/ml) for twice-daily DRV/r.
Discussion
The results from this randomized, phase III trial in treatment-experienced patients with no DRV RAMs at screening demonstrated that over 48 weeks of treatment, once-daily DRV/r 800/100 mg was noninferior in virologic response to twice-daily DRV/r 600/100 mg.
Patients enrolling in ODIN had a broad range of treatment experience; approximately, half were protease inhibitor-naive on study entry, 28.3% had previously used at least two protease inhibitors, and 87.5% had previously received at least one NNRTI. The previous antiretroviral experience of the ODIN population was broadly similar to that of the TITAN study, with similar proportions of patients having used at least two protease inhibitors [7] ; however, more patients enrolled in ODIN were protease inhibitor-naive (46.1%) than patients randomized to DRV/r in TITAN (31.5%). In contrast, patients in ODIN were much less treatment-experienced than those in the POWER trials [8, 9] , in which the vast majority had previously used at least two protease inhibitors. In ODIN, the OBR consisted of at least two NRTIs; 71.7% of patients used at least two active NRTIs, compared with 65.3% of DRV/r patients in TITAN.
Available data from routine clinical practice suggest that most treatment-experienced patients do not harbor DRV RAMs: among patients with protease inhibitor resistance, 83.4% of 207 910 isolates [16] and 75% of 98 000 isolates [17] had no DRV RAMs. Furthermore, in the TITAN Once-daily vs. twice-daily darunavir/r Cahn et al. 935 trial, 82.6% of patients harbored no DRV RAMs at baseline [18] . Therefore, data from the ODIN study may be applicable to a large group of treatment-experienced patients currently under treatment.
Evaluation of the results by screening HIV-1 RNA showed a trend toward higher response rates in patients with HIV-1 RNA of 50 000 copies/ml or less than those with more than 50 000 copies/ml. Nonetheless, the rates of virologic suppression were similar between once-daily and twice-daily DRV/r. Furthermore, Cahn et al. [19] reported that virologic response rates were comparable between once-and twice-daily DRV/r regardless of number of protease inhibitors previously used (82.2 vs. 79.6% with no protease inhibitor prior use; 64.9 vs. 63.6% with one prior protease inhibitor; and 62.4 vs. 63.4% with at least two prior protease inhibitors). A trend toward lower response rates was observed in patients who had previously used at least one protease inhibitor; this was not accounted for by baseline resistance.
The findings in this study are consistent with previous data in treatment-experienced patients with no DRV RAMs. In ODIN, 72.1 and 70.9% of once-daily and twice-daily DRV/r patients, respectively, achieved HIV-1 RNA less than 50 copies/ml at week 48. In the subgroup of treatment-experienced patients with no baseline DRV RAMs in TITAN, 70.6% (168/238) of those receiving twice-daily DRV/r 600/100 mg achieved HIV-1 RNA less than 50 copies/ml [20] . In the subgroup of highly treatment-experienced patients with no baseline DRV RAMs in POWER, 66.7% (14/21) and 62.1% (18/29) of patients receiving once-daily DRV/r 800/100 mg and twice-daily DRV/r 600/100 mg, respectively, achieved HIV-1 RNA less than 50 copies/ml [10] .
Both once-daily and twice-daily DRV/r were associated with a low rate of virologic failure. The small difference in virologic failure rates (22.1 vs. 18.2% for once-daily and twice-daily DRV/r, respectively) between treatment groups can mostly be explained by fewer neversuppressed patients in the twice-daily DRV/r arm based on the TLOVR nonvirologic failure-censored algorithm. This disparity is mainly due to a higher frequency of twice-daily compared with once-daily DRV/r patients discontinuing before week 12; within this definition of virologic failure, patients discontinuing before week 12 were not counted as never-suppressed. In patients with virologic failure, the development of resistance was rare and only one patient developed primary protease inhibitor mutations and DRV RAMs. Loss of susceptibility to protease inhibitors upon virologic failure was also infrequent.
DRV/r administered both once-daily and twice-daily was generally safe and well tolerated with few discontinuations due to adverse events. There were no new clinically relevant safety findings compared with the known safety profile of DRV/r [6, 7, 21] . There was a lower overall incidence of SAEs and grade 3-4 adverse events in the once-daily arm compared with the twice-daily DRV/r arm, but no specific patterns in the incidence of individual SAEs or grade 3-4 adverse events were apparent. A low frequency of gastrointestinal adverse events was reported for both arms, including a low incidence of at least possibly treatment-related diarrhea. It should be noted that ODIN was an open-label trial, which may have biased reporting of adverse events.
The incidence of grade 2-4 increases in total cholesterol, LDL cholesterol, and triglycerides were significantly lower in the once-daily than the twice-daily DRV/r arm. The incidence of grade 2-4 triglycerides with oncedaily DRV/r was approximately half that of twice-daily DRV/r; this may result at least partly from the lower dose of ritonavir with once-daily dosing, as ritonavir has previously been linked to increases in triglycerides [22, 23] . The incidence of grade 2-4 triglycerides with twice-daily DRV/r here was lower than in DRV/r patients in TITAN (11.0 vs. 19.7%, respectively), in which patients also received a 200 mg total daily dose of ritonavir [7] . In treatment-naive patients receiving once-daily DRV/r 800/100 mg in ARTEMIS, the incidence of grade 2-4 increases in triglycerides (2.9%) [24] was slightly lower than that in this trial (5.2% for once-daily dosing). This may have been due to the choice of background regimen, as the use of abacavir/ lamivudine, zidovudine/lamivudine, or stavudine/ lamivudine (used in this study) has previously been shown to lead to larger increases in lipid parameters than for tenofovir/emtricitabine (the fixed background in ARTEMIS) [25] .
Although some variability was seen between the three adherence measures used, similar levels of adherence were reported for once-daily and twice-daily dosing in this treatment-experienced population. This lack of difference between once-daily and twice-daily dosing may result from the clinical trial setting and might not be reproduced in routine clinical practice [26] .
Pharmacokinetic evaluations revealed DRV trough concentrations were comparable to previous findings [27, 28] . Once-daily DRV/r dosing resulted in lower DRV trough concentrations than for twice-daily dosing. However, comparable efficacy to the twice-daily DRV/r arm was observed, confirming that adequate DRV levels were achieved with once-daily DRV/r dosing in this population. In addition, these findings are consistent with the long terminal DRV half-life of approximately 15 h [29] , suggesting that once-daily dosing with DRV/r 800/ 100 mg is appropriate. Plasma concentration levels achieved with once-daily DRV/r 800/100 mg have been shown to be sufficient in treatment-naive patients [24] ; ODIN has now broadened this finding to apply to the treatment-experienced population who have no DRV RAMs.
In conclusion, both once-daily (800/100 mg) and twicedaily DRV/r (600/100 mg) were associated with high rates of virologic suppression, a low incidence of virologic failure, and a favorable safety and tolerability profile in treatment-experienced patients with no DRV RAMs. Over 48 weeks of treatment, once-daily DRV/r 800/ 100 mg demonstrated noninferior efficacy, as well as safety benefits, compared with twice-daily DRV/r 600/ 100 mg. The findings from this primary analysis support the use of DRV/r 800/100 mg as a once-daily option in treatment-experienced, HIV-1-infected adults with no DRV RAMs.
